LT3536776T - Naujos stuburinių ląstelės ir metodai, skirti rekombinantinei dominančio polipeptido raiškai - Google Patents

Naujos stuburinių ląstelės ir metodai, skirti rekombinantinei dominančio polipeptido raiškai

Info

Publication number
LT3536776T
LT3536776T LTEP19161388.4T LT19161388T LT3536776T LT 3536776 T LT3536776 T LT 3536776T LT 19161388 T LT19161388 T LT 19161388T LT 3536776 T LT3536776 T LT 3536776T
Authority
LT
Lithuania
Prior art keywords
polypeptide
interest
methods
vertebrate cells
recombinantly expressing
Prior art date
Application number
LTEP19161388.4T
Other languages
English (en)
Inventor
Holger Laux
Sandrine Romand
Ursula Bodendorf
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53682742&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3536776(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT3536776T publication Critical patent/LT3536776T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21109—Matriptase (3.4.21.109)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Electro-optical investigation, e.g. flow cytometers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • G01N15/01—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology
LTEP19161388.4T 2014-04-29 2015-04-29 Naujos stuburinių ląstelės ir metodai, skirti rekombinantinei dominančio polipeptido raiškai LT3536776T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461985589P 2014-04-29 2014-04-29
US201461994310P 2014-05-16 2014-05-16

Publications (1)

Publication Number Publication Date
LT3536776T true LT3536776T (lt) 2024-01-25

Family

ID=53682742

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP15739327.3T LT3137595T (lt) 2014-04-29 2015-04-29 Naujos stuburinių ląstelės ir dominančio polipeptido rekombinantinės raiškos būdai
LTEP19161388.4T LT3536776T (lt) 2014-04-29 2015-04-29 Naujos stuburinių ląstelės ir metodai, skirti rekombinantinei dominančio polipeptido raiškai

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP15739327.3T LT3137595T (lt) 2014-04-29 2015-04-29 Naujos stuburinių ląstelės ir dominančio polipeptido rekombinantinės raiškos būdai

Country Status (17)

Country Link
US (2) US11512335B2 (lt)
EP (3) EP3137595B1 (lt)
JP (1) JP6636453B2 (lt)
KR (1) KR102307278B1 (lt)
CN (1) CN106255749A (lt)
AU (1) AU2015254913B2 (lt)
CA (1) CA2947198C (lt)
DK (2) DK3536776T3 (lt)
ES (1) ES2731246T3 (lt)
IL (1) IL248184B (lt)
LT (2) LT3137595T (lt)
MX (1) MX368664B (lt)
PL (2) PL3536776T3 (lt)
PT (2) PT3536776T (lt)
RU (1) RU2710726C2 (lt)
SG (1) SG11201608358VA (lt)
WO (1) WO2015166427A2 (lt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
US10781435B2 (en) 2017-06-22 2020-09-22 Catalyst Biosciences, Inc. Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
WO2019180607A1 (en) * 2018-03-19 2019-09-26 Centre For Cellular And Molecular Platforms A vector, a host cell and a method thereof
AU2020347945A1 (en) 2019-09-18 2022-03-31 Novartis Ag NKG2D fusion proteins and uses thereof
BR112022014493A2 (pt) 2020-02-05 2022-09-20 Novartis Ag Célula de cho que expressa heterodímeros de il-15
EP4150085A1 (en) * 2020-05-11 2023-03-22 Genentech, Inc. Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
WO2023223219A1 (en) * 2022-05-19 2023-11-23 Novartis Ag IMPROVED PROTEIN PRODUCTION USING miRNA TECHNOLOGY

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
US5371198A (en) * 1991-12-16 1994-12-06 Novo Nordisk A/S Method for protection of proteolysis-susceptible protein during protein production in a fluid medium
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
WO2002008392A2 (en) 2000-07-25 2002-01-31 Bayer Aktiengesellschaft Regulation of human matriptase-like serine protease
CA2454731C (en) * 2001-08-27 2010-11-02 Genentech, Inc. A system for antibody expression and assembly
CN101124484A (zh) * 2002-10-02 2008-02-13 催化剂生物科学有限公司 制备与筛选改变特异性蛋白酶的方法
PT1601776E (pt) 2003-03-11 2008-09-17 Serono Lab Vectores de expressão que compreendem o promotor ie2 do mcmv
DK1781814T3 (da) * 2004-08-10 2010-05-03 Cardiff Biolog Ltd Fremgangsmåder og kit til prognose af brystkræft
CA2592249C (en) 2004-12-20 2014-07-29 Amgen Fremont Inc. Binding proteins specific for human matriptase
US7632509B2 (en) * 2005-07-19 2009-12-15 Biosante Pharmaceuticals, Inc. Methods to express recombinant proteins from lentiviral vectors
CA2696263C (en) 2007-08-15 2017-06-13 Bing Liu Monospecific and multispecific antibodies and method of use
PT2227549E (pt) 2007-12-21 2015-10-08 Novartis Ag Sistema de seleção para cultura de células eucarióticas com base num gene de recetor de folato ligado à membrana
AU2010215761B2 (en) 2009-02-23 2017-04-06 Cytomx Therapeutics, Inc Proproteins and methods of use thereof
PT2401377T (pt) 2009-02-27 2016-08-18 Novartis Ag Sistema de vectores de expressão compreendendo dois marcadores de selecção
WO2010124200A2 (en) * 2009-04-23 2010-10-28 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for cancer
SG185038A1 (en) 2010-04-26 2012-11-29 Novartis Ag Improved cell culture medium
US9365853B2 (en) * 2011-06-02 2016-06-14 SOCPRA Sciences Sante et Humaines S.E.C. Matriptase inhibitors and uses thereof against orthomyxoviridae infections
JP2015516813A (ja) * 2012-04-27 2015-06-18 シトムクス セラピューティクス，インコーポレイティド 上皮成長因子受容体を結合する活性化可能抗体及びその使用方法
CN104661677A (zh) 2012-06-22 2015-05-27 西托姆克斯治疗公司 抗Jagged 1/Jagged 2交叉反应抗体、可活化的抗Jagged抗体及其使用方法
EP3015475A1 (en) * 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens

Also Published As

Publication number Publication date
ES2731246T3 (es) 2019-11-14
MX2016014222A (es) 2017-05-04
PT3536776T (pt) 2024-01-12
SG11201608358VA (en) 2016-11-29
DK3536776T3 (da) 2024-01-15
PL3137595T3 (pl) 2019-09-30
PL3536776T3 (pl) 2024-03-25
JP6636453B2 (ja) 2020-01-29
LT3137595T (lt) 2019-06-25
BR112016024534A2 (pt) 2017-10-10
IL248184B (en) 2021-03-25
EP4332231A2 (en) 2024-03-06
EP3536776B1 (en) 2023-10-25
EP3536776A1 (en) 2019-09-11
KR20160147919A (ko) 2016-12-23
PT3137595T (pt) 2019-06-19
RU2016145928A (ru) 2018-05-29
US20230323419A1 (en) 2023-10-12
EP3137595B1 (en) 2019-03-13
WO2015166427A3 (en) 2016-01-14
KR102307278B1 (ko) 2021-09-30
CA2947198C (en) 2023-01-17
CN106255749A (zh) 2016-12-21
IL248184A0 (en) 2016-11-30
CA2947198A1 (en) 2015-11-05
WO2015166427A2 (en) 2015-11-05
JP2017514484A (ja) 2017-06-08
RU2710726C2 (ru) 2020-01-10
RU2016145928A3 (lt) 2018-12-26
US11512335B2 (en) 2022-11-29
MX368664B (es) 2019-10-10
EP3137595A2 (en) 2017-03-08
AU2015254913A1 (en) 2016-10-27
DK3137595T3 (da) 2019-06-17
US20170044587A1 (en) 2017-02-16
AU2015254913B2 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
HK1232239A1 (zh) 細胞穿透肽及其製造和使用方法
EP3240799A4 (en) S-alkylated hepcidin peptides and methods of making and using thereof
IL248361A0 (en) Recombinant host cell for expression of desired proteins
IL248184B (en) Novel invertebrate cells and methods for recombinant expression of a desired polypeptide
IL245854A0 (en) New eukaryotic cells and methods for recombinant expression of the desired product
HK1244460A1 (zh) 絲氨酸融合多肽和其使用方法
IL245856B (en) New eukaryotic cells and methods for recombinant expression of the desired product
IL237993A0 (en) Incorporating pixels and operating methods
IL246642A0 (en) Materials and methods for quantifying pld-1 protein levels
EP3268477A4 (en) Structure based methods for modification of pip-72 polypeptides and pip-72 polypeptides derived therefrom
EP3092248A4 (en) Fusion polypeptides and methods of use
IL250178A0 (en) Methods and preparations for the expression of peptides in the cell
IL247448A0 (en) Peptides and methods of use
GB2527908B (en) Closure means and method of use thereof
PL2957516T3 (pl) Pojemnik i sposób jego produkcji